| Literature DB >> 24645879 |
Piotr J Mak1, Abhinav Luthra, Stephen G Sligar, James R Kincaid.
Abstract
CYP19A1, or aromatase, a cytochrome P450 responsible for estrogen biosynthesis in humans, is an important therapeutic target for the treatment of breast cancer. There is still controversy surrounding the identity of reaction intermediate that catalyzes carbon-carbon scission in this key enzyme. Probing the oxy-complexes of CYP19A1 poised for hydroxylase and lyase chemistries using resonance Raman spectroscopy and drawing a comparison with CYP17A1, we have found no significant difference in the frequencies or isotopic shifts for these two steps in CYP19A1. Our experiments implicate the involvement of Compound I in the terminal lyase step of CYP19A1 catalysis.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24645879 PMCID: PMC3985783 DOI: 10.1021/ja500054c
Source DB: PubMed Journal: J Am Chem Soc ISSN: 0002-7863 Impact factor: 15.419
Figure 1Catalytic cycle for cytochrome P450.[3]
Figure 2Proposed pathway for aromatization reaction of androstenedione by human CYP19A1.
Figure 3High frequency rR spectra of AD-bound oxy CYP19A1 (A) and the difference traces, 16O2–18O2 in H2O buffer (B) and 16O2–18O2 in D2O buffer (C). Inset shows corresponding difference traces in low frequency region.
Figure 4High frequency rR spectra of 19-oxo-AD-bound oxy CYP19A1 (A) and the difference traces, 16O2–18O2 in H2O buffer (B) and 16O2–18O2 in D2O buffer (C). Inset shows corresponding difference traces in low frequency region.